Tag: percutaneous coronary intervention

Delirium Common, Costly After Mitral, Tricuspid Valve Repair

Delirium occurred in nearly 1-in-10 elderly patients after percutaneous mitral and tricuspid valve repair and signaled longer hospital stays and worse survival, a new study...

Radial-to-Backup Artery Switch Adds Limited Risk in ACS PCI

There’s a price to pay for a failed radial artery attempt in invasively managed patients with acute coronary syndrome (ACS), but it may not be...

Ticking All the Right Boxes for Same-Day Discharge PCI

The American College of Cardiology has released a new expert consensus decision pathway to provide practical guidance on same-day discharge after percutaneous coronary intervention (PCI)....

Physician-Level PCI Mortality Data May Be Misleading

Publicly reported percutaneous coronary intervention (PCI) mortality data may be misleading with regard to cardiologists who perform PCI at multiple centers, new research suggests. Dr...

Renowned Interventional Cardiologist Dies of COVID-19

The interventional cardiology community is mourning the loss of Prof Anthony “Tony” Gershlick, MBBS, who died November 20 of COVID-19. He was 69. Gershlick was...

Clopidogrel Bests Ticagrelor for Elective PCI

Ticagrelor failed to unseat clopidogrel as the guideline-recommended P2Y12 inhibitor of choice in patients undergoing elective percutaneous coronary intervention for stable CAD in the randomized...

The ‘Grubby’ Affair of the EXCEL Trial and the European Guidelines

“I disapprove of what you say, but I will defend to the death your right to say it.” The choice of the secretary general of...

Advisory Panel Balks at Neovasc Reducer for Refractory Angina

More than 10 hours of testimony and debate failed to convince a US Food and Drug Administration (FDA) expert advisory panel that existing evidence reasonably...

Optimal Post-PCI FFR Often Missed

Optimization of fractional flow reserve (FFR) after angiographically successful percutaneous coronary intervention (PCI) did not impact clinical outcomes but significantly reduced the proportion of patients...

More Support for Shorter DAPT in High Bleeding Risk PCI

Select high bleeding risk (HBR) patients can safely receive just 1 or 3 months of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) without...

Tightly iFR-Optimized PCI May Cut Cardiac Event Risk

As much as intracoronary physiologic measures can help operators identify potential ischemia-producing targets for percutaneous coronary intervention (PCI), they may also verify whether the procedure...

Study Questions Routine Long-term Beta-Blocker Post MI

Current American and European guidelines recommending long-term beta-blocker therapy following an acute MI appear to be obsolete in the modern reperfusion era, suggests an analysis...

Early Evolocumab Quickly Lowers LDL After Primary PCI

Early administration of evolocumab significantly reduced levels of LDL cholesterol in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention, according to data...

Trimetazidine Fizzles for Post-PCI Angina

Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a non–ST-elevated myocardial infarction (MI),...

CMS Teams With ACC to Make Quality Measures More Relevant

The Centers for Medicare & Medicaid Services (CMS) has partnered with the American College of Cardiology (ACC) to include several National Cardiovascular Data Registry (NCDR)...

ESC 2020 Looks to Make its Mark in ‘New Era’ of Virtual Meetings

The coronavirus may have quashed plans to socialize and stroll the canals of Amsterdam while at this year’s European Society of Cardiology (ESC) Congress, but...

Female Benefit With CABG Vanishes by 10 Years

The beneficial effect on all-cause mortality of coronary artery bypass grafting surgery (CABG) observed at 4 and 5 years in women with complex coronary disease...

Acetaminophen Beats Fentanyl in STEMI

Swapping out intravenous fentanyl in favor of IV acetaminophen in patients with ST-elevation MI (STEMI) provides comparable pain relief but with desirably higher blood levels...

Post-PCI Mortality Higher in Blacks vs Whites, Comorbidities Aside

A combined analysis of 10 prospective trials, intended to shed light on racial disparities in percutaneous coronary intervention (PCI) outcomes, saw sharply higher risks of...

PCI Comes Up Short for Most, but Not All Multivessel CTOs

Percutaneous coronary intervention (PCI) is associated with greater risks for long-term adverse cardiovascular events than surgery in patients with chronic total occlusion (CTO) and multivessel...

Chewed Prasugrel for Primary PCI? Forget It!

Tirofiban is far superior to cangrelor at achieving rapid and potent inhibition of platelet aggregation in patients undergoing primary percutaneous coronary intervention for ST-elevation MI....

SCAI Weighs In on PCI at Ambulatory Surgical Centers

The Society for Cardiovascular Angiography and Interventions (SCAI) has issued a position paper on percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs) that makes...

TWILIGHT Outcomes Hold Regardless of Stent Platform

A new TWILIGHT analysis shows similar efficacy among high-risk patients treated with bioabsorbable polymer and durable-polymer stents and a consistent benefit of ticagrelor (Brilinta, Brilique;...

Consensus Recommendations on AMI Management During COVID-19

What your doctor is reading on Medscape.com: APRIL 22, 2020 — A consensus statement from the American College of Cardiology (ACC), the American College...

Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin

The VOYAGER PAD results from more than 6,500 patients created the biggest evidence base by far ever collected from patients with symptomatic peripheral artery disease...